SO many openings!

Discussion in 'Janssen' started by anonymous, Mar 7, 2018 at 11:18 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Any idea why there are a ton of Area Biz Specialist openings? I thought it was a good gig, am I missing something?
     

  2. anonymous

    anonymous Guest

    ......so little to do.
     
  3. anonymous

    anonymous Guest

    "Little"?? I thought they were working hard helping me meet me goals!
     
  4. anonymous

    anonymous Guest

    These are all expansion positions! Come on guys!! Things are going great. Don’t listen to those people that are trying to pull you down. This company has never been stronger. We are expanding, isn’t that great! Beeee positive
     
  5. anonymous

    anonymous Guest

    We. Can’t. See. Our. Targeted. Customers.

    Reps don’t have to listen to anyone or read CP posts. Reps know the reality of what we face in the field, and the farce that is management sales direction.

    There. Is. No. Access.

    By all means, continue cheerleading.
     
  6. anonymous

    anonymous Guest

    No one wants to realistically hear that you cannot see your customers. They do not want to give up cushy $, benefits, etc. They want job protection and they all do not care. One big ripoff to customers, institutions, people, industry and society.
     
  7. anonymous

    anonymous Guest

    The reality is that we have 2 biosimilar versions of Remicade, with more coming. Aria is a dud. Stelera, Simponi, and Aria have limited patent life until 2024. Biosimilar humira and orencia are also coming very soon. We have no pipeline. The entire immunology market is about to be a sinking ship.
     
  8. anonymous

    anonymous Guest

    Just so I understand you;
    You can’t see practitioners and most office staff.
    You make up calls while sitting at home to appease management.
    Your drugs are not well received by the immunology market place.
    You have nothing coming to infer a rebound in your market.

    The generic/biosim products are about to take the revenue that has been paying your bills for years.
    Is that about right? Let me guess...”we are as strong as ever”, and “I repeat we are not having a downsizing”. Does that sound familiar? Well I survived the OBI fall and I can tell you that without Remicade we would all have been let go. Unfortunately we aren’t exactly sitting on another 8 billion drug. So if you aren’t looking for another position you may want to start. Anyone left at JBI will be in for an ugly time in terms of pay and ability to survive. I’m taking my own advice and hope to quit in the next few months. I might even decide to double dip for a time to make up for the shorting of my bonus.
     
  9. anonymous

    anonymous Guest

    ^ Yup. FIFY